Egypt approves EVA and Lilly’s insulin glargine

The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly (NYSE: LLY).

The partnership, launched in 2022, aims to deliver affordable insulin to over one million people annually in low- and middle-income countries, particularly in Africa. EVA’s newly established biologics facility has now released its first batch of the locally manufactured product.

The collaboration includes Lilly supplying active pharmaceutical ingredients at reduced prices and a pro-bono technology transfer to enable EVA Pharma to locally formulate, fill, and finish insulin products.